

Curriculum Vitae  
**Deborah Gardner Nixon, MD**

**Practice Address:** Dermatology Specialists of Charlotte  
8936 Blakeney Professional Drive  
Charlotte, NC 28277  
[Deborah.nixon@dscmd.com](mailto:Deborah.nixon@dscmd.com)

**Site Affiliation:** DJL Clinical Research, PLLC  
2017-Present 431 N Wendover Rd  
Charlotte, NC 28211

**Education:**

1995-1998	Residency in Dermatology
1997-1998	Chief Administrative Resident University of South Florida Medical Center Tampa, Florida
1993-1995	Residency in Internal Medicine Georgetown University Medical Center Washington, DC
1992-1993	Internship in Internal Medicine Vanderbilt University Medical Center Nashville, Tennessee
1988-1992	Doctor of Medicine University of North Carolina at Chapel Hill School of Medicine Chapel Hill, North Carolina
1984-1988	Bachelor of Science in Zoology Duke University Durham, North Carolina

**Professional Experience:**

2006-Present	Dermatologist/Owner Dermatology Specialists of Charlotte
2000-2006	Dermatologist Carolina Dermatology
1998-2000	Dermatologist The Dermatology Group, PA

**Licensure/Certifications:**

- 1998-Present Dermatology Board Certified – State of North Carolina
- 1995-2005 Internal Medicine Board Certified– State of North Carolina

Curriculum Vitae  
**Deborah Gardner Nixon, MD**

**Professional Memberships:**

1995-Present	Fellow of the American Academy of Dermatology
2003-Present	Fellow of the American Society of Dermatologic Surgeons
1998-Present	North Carolina Dermatology Association
1999-Present	Mecklenburg County Medical Society

**Clinical Research:**

**Sub-Investigator** – Abbvie: A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) –SELECT – PsA 2 (2017)

**Principal Investigator** – Cutanea Life Sciences, Inc: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 in Subjects 2 years of age or older with Cutaneous Common Warts (2017)

**Principal Investigator** – Vanda: A Randomized, Double-Blind, Placebo Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis. 2019

**Principal Investigator** – Chemocentryx: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa. 2019

**Principal Investigator** – Skintech: A Randomized, Double Blind, Phase 2, Comparative 16-Week Study of ACCUMAX SUBLINGUAL (Diindolylmethane, DIM + Vitamin A) and Quercetin vs Placebo in Participants with Moderate to Severe Acne Vulgaris. 2019

**Principal Investigator** – Eli Lilly: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata. BRAVE-AA2. 2019

**Principal Investigator** – Astrazeneca: A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

**Principal Investigator** – Concert Pharmaceuticals: A Double-blind, Randomized, Placebo-controlled study to evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

**Principal Investigator** – Concert: A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata


**Principal Investigator** – Concert: A Multicenter, Open-label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata


Curriculum Vitae  
Deborah Gardner Nixon, MD

**Principal Investigator** – AnaptysBio: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects with Moderate to Severe Alopecia Areata

**Principal Investigator** – Janssen: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Skin of Color who have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis

My signature verifies the information in this document is accurate and updated appropriately.

  
\_\_\_\_\_  
Signature

  
\_\_\_\_\_  
Date

